321.92
Praxis Precision Medicines Inc stock is traded at $321.92, with a volume of 448.98K.
It is down -2.74% in the last 24 hours and up +10.97% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$330.99
Open:
$333.79
24h Volume:
448.98K
Relative Volume:
1.04
Market Cap:
$8.97B
Revenue:
$7.46M
Net Income/Loss:
$-303.27M
P/E Ratio:
-23.90
EPS:
-13.4668
Net Cash Flow:
$-249.12M
1W Performance:
-5.55%
1M Performance:
+10.97%
6M Performance:
+61.50%
1Y Performance:
+784.15%
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
PRAX
Praxis Precision Medicines Inc
|
321.92 | 9.22B | 7.46M | -303.27M | -249.12M | -13.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision Medicines Prepares for Major FDA Decisions in 2026 - HarianBasis.co
Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology - Insider Monkey
Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential - Insider Monkey
Praxis Precision shares rally on price target hikes: Analyst sees upside as high as 100% for stock - MSN
Praxis Precision gains as lead asset accepted for FDA review - MSN
(PRAX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Praxis Precision Medicines (PRAX) Projected to Post Earnings on Friday - MarketBeat
Praxis Precision Medicines (PRAX): One of the Best Upside Stocks - Insider Monkey
Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN
PRAX (Praxis Precision Medicines Inc.) shares rise nearly 7 percent despite wider than expected Q4 2025 per share loss.Stability Report - Cổng thông tin điện tử Tỉnh Sơn La
5 Best Upside Stocks to Buy According to Analysts - Insider Monkey
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $567 - Moomoo
Praxis Precision Medicines (PRAX) Is Up 8.1% After FDA Accepts Ulixacaltamide NDA for Essential Tremor - simplywall.st
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200 - Moomoo
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $545 - 富途牛牛
Massachusetts Financial Services Co. MA Purchases New Shares in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX) - MSN
Needham Raises Price Target for Praxis Precision Medicine (PRAX) - GuruFocus
Why is Praxis Precision stock soaring Tuesday? - MSN
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 5.1%Time to Sell? - MarketBeat
Deutsche Bank Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $437 - Moomoo
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $437 From $412, Maintains Buy Rating - marketscreener.com
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - 富途牛牛
PRAX Reiterated by Needham -- Price Target Maintained at $510 - GuruFocus
FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor By Investing.com - Investing.com South Africa
FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor - Investing.com Australia
Praxis Precision NDA for Ulixacaltamide in Essential Tremor - TipRanks
FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance - Investing.com UK
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance By Investing.com - Investing.com South Africa
Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review - Investing.com UK
Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review By Investing.com - Investing.com South Africa
Praxis Precision Medicines stock rating reiterated at Buy by BTIG By Investing.com - Investing.com India
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):